| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Alalevonadifloxacin targets bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and survival. By inhibiting DNA gyrase, the compound prevents the supercoiling of bacterial DNA necessary for replication and transcription. Inhibition of topoisomerase IV interferes with the decatenation of replicated DNA, preventing chromosome segregation during cell division. This dual targeting results in potent bactericidal activity against a broad spectrum of bacteria, including drug-resistant strains.
|
|---|---|
| ln Vitro |
In vitro, Alalevonadifloxacin demonstrates potent antibacterial activity against a broad spectrum of bacteria, including Gram-positive, Gram-negative, and anaerobic pathogens. The compound shows notable potency against methicillin-resistant Staphylococcus aureus (MRSA). As a quinolone antibacterial, it inhibits bacterial DNA gyrase and topoisomerase IV. The prodrug is converted to the active moiety levonadifloxacin, which exerts its antibacterial effects. Its activity has been characterized in various bacterial strains, with efficacy against drug-resistant organisms.
|
| ln Vivo |
In vivo, Alalevonadifloxacin is orally active with ~89% oral bioavailability. The prodrug is converted to levonadifloxacin, which distributes to tissues including plasma, epithelial lining fluid, and alveolar macrophages. Phase II clinical trials are ongoing for the treatment of methicillin-resistant Staphylococcus aureus infections and skin and soft tissue infections. Intrapulmonary pharmacokinetic studies have been conducted in healthy adult subjects. The compound shows potential for treating both systemic and respiratory infections.
|
| Enzyme Assay |
The in vitro antibacterial susceptibility assay for Alalevonadifloxacin involves testing the compound against various bacterial strains using standard methods such as broth microdilution according to CLSI guidelines. Bacterial inocula are prepared from overnight cultures and adjusted to the appropriate density. Serial dilutions of the compound are prepared in growth medium, and bacterial suspensions are added. Plates are incubated at 37°C for 18-24 hours, and the minimum inhibitory concentration (MIC) is determined. DNA gyrase and topoisomerase IV inhibition is assessed by measuring the compound's ability to inhibit supercoiling and decatenation activities of purified enzymes in vitro.
|
| Cell Assay |
For in vitro cellular assays, Alalevonadifloxacin is tested in bacterial cultures to assess its effects on bacterial growth and viability. Bacteria are treated with the compound at various concentrations for defined periods. Bacterial growth is measured by optical density at 600 nm. Viability is assessed by colony counting on agar plates. DNA synthesis inhibition is measured by incorporation of radiolabeled thymidine. The compound's effects on bacterial morphology are assessed by microscopy. Resistance development is studied by serial passage in the presence of sub-inhibitory concentrations. The prodrug's conversion to levonadifloxacin is assessed in cell culture or liver microsome preparations.
|
| Animal Protocol |
In vivo animal experiments for Alalevonadifloxacin would typically use mouse models of bacterial infection. Animals are infected with bacterial pathogens and treated with the compound orally or intravenously at various doses and schedules. Survival is monitored as the primary endpoint. Bacterial burden in tissues is measured by colony counting. Pharmacokinetic studies are conducted to determine the compound's bioavailability, distribution, and elimination. Intrapulmonary pharmacokinetics have been studied in healthy human subjects, with levonadifloxacin concentrations measured in plasma, epithelial lining fluid, and alveolar macrophages following oral administration of alalevonadifloxacin.
|
| Molecular Formula |
C22H26FN3O5
|
|---|---|
| Molecular Weight |
431.457349300385
|
| Exact Mass |
431.185
|
| CAS # |
706809-20-3
|
| Related CAS # |
396132-82-4 (HCl);706809-20-3;948895-94-1 ( mesylate);
|
| PubChem CID |
16734914
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.7
|
| tPSA |
113
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
781
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
|
| InChi Key |
OUXXDXXQNWKOIF-RYUDHWBXSA-N
|
| InChi Code |
InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
|
| Chemical Name |
(12S)-8-[4-[(2S)-2-aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
|
| Synonyms |
WCK2349 Alalevonadifloxacin WCK-2349 WCK 2349
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3177 mL | 11.5886 mL | 23.1771 mL | |
| 5 mM | 0.4635 mL | 2.3177 mL | 4.6354 mL | |
| 10 mM | 0.2318 mL | 1.1589 mL | 2.3177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.